Binding of sulfonium-ion analogues of Di-epi-Swainsonine and 8-epi-Lentiginosine to Drosophila Golgi α-mannosidase II: The role of water in inhibitor binding

Proteins: Structure, Function and Genetics

Volumn 71, Issue 3, 2008, Pages 1484-1496

  Kumar, Nag S ^a   Kuntz, Douglas A ^b   Wen, Xin ^c   Pinto, B Mario ^a   Rose, David R ^b,d  

^a SIMON FRASER UNIVERSITY   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c NANKAI UNIVERSITY   (China)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bicyclic sulfonium salts; Glycosidase inhibitor; Inhibitor docking; Lentiginosine; Solvent substructure; Swainsonine; X ray crystallography

Indexed keywords

2 EPISWAINSONINE; 8 EPILENTIGINOSINE; ALPHA MANNOSIDASE; ALPHA MANNOSIDASE II; GLYCOSIDASE INHIBITOR; HYDROXYL GROUP; SULFONIUM DERIVATIVE; UNCLASSIFIED DRUG; WATER;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DROSOPHILA; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; GOLGI COMPLEX; IC 50; INHIBITION KINETICS; MOLECULAR DOCKING; PREDICTION; PRIORITY JOURNAL; SYNTHESIS; WATER STRUCTURE; X RAY CRYSTALLOGRAPHY;

ALKALOIDS; ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DROSOPHILA PROTEINS; MANNOSIDASES; PROTEIN BINDING; SULFONIUM COMPOUNDS; SWAINSONINE; WATER;

EID: 42449154261     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21850     Document Type: Article

References (49)

1. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. Essentials of glycobiology. NY: Cold Spring Harbor Laboratory Press; 1999.
2. Tayler ME, Drickamer K. Introduction to glycobiology. NY: Oxford University Press; 2003.
3. Herscovics A. Comprehensive natural products chemistry. In: Pinto BM, Barton DHR, Nakanishi K, Meth-Cohn O, editors. UK: Elsevier; 1999.
4. Asano N, Nash RJ, Molyneux RJ, Fleet GWJ. Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron: Asymmetry 2000;11:1645-1680.
5. Watson AA, Fleet GWJ, Asano N, Molyneux RJ, Nash RJ. Polyhydroxylated alkaloids - natural occurrence and therapeutic applications. Phytochemistry 2001;56:265-295.
6. Lillelund VH, Jensen HH, Liang XF, Bols M. Recent developments of transition-state analogue glycosidase inhibitors of non-natural product origin. Chem Rev 2002;102:515-553.
7. Elbein AD. Inhibitors of the biosynthesis and processing of N-linked oligosaccharide chains. Annu Rev Biochem 1987;56:497-534.
8. Elbein AD. Glycosidase inhibitors - inhibitors of N-linked oligosaccharide processing. FASEB J 1991;5:3055-3063.
9. Winchester B, Fleet GWJ. Amino-sugar glycosidase inhibitors - versatile tools for glycobiologists. Glycobiology 1992;2:199-210.
10. Stutz AE. Iminosugars as glycosidase inhibitors: nojirimycin and beyond. NY: Wiley-VCH, Weinheim; 1999.
11. McCarter JD, Withers SG. Mechanisms of enzymatic glycoside hydrolysis. Curr Opin Struct Biol 1994;4:885-892.
12. Ly HD, Withers SG. Mutagenesis of glycosidases. Annu Rev Biochem 1999;68:487-522.
13. Pastuszak I, Molyneux RJ, James LF, Elbein AD. Lentiginosine, a dihydroxyindolizidine alkaloid that inhibits amyloglucosidase. Biochemistry 1990;29:1886-1891.
14. Cenci di Bello I, Fleet G, Namgoong SK, Tadano K, Winchester B. Structure-activity relationship of swainsonine. Inhibition of human alpha-mannosidases by swainsonine analogues. Biochem J 1989;259:855-861.
15. Haraguchi M, Gorniak SL, Ikeda K, Minami Y, Kato A, Watson AA, Nash RJ, Molyneux RJ, Asano N. Alkaloidal components in the poisonous plant, Ipomoea carnea (Convolvulaceae). J Agric Food Chem 2003;51:4995-5000.
16. Ikeda K, Kato A, Adachi I, Haraguchi M, Asano N. Alkaloids from the poisonous plant Ipomoea carnea: effects on intracellular lysosomal glycosidase activities in human lymphoblast cultures. J Agric Food Chem 2003;51:7642-7646.
17. Goss PE, Baptiste J, Fernandes B, Baker M, Dennis JW. A phase-I study of swainsonine in patients with advanced malignancies. Cancer Res 1994;54:1450-1457.
18. Goss PE, Reid CL, Bailey D, Dennis JW. Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin Cancer Res 1997;3:1077-1086.
19. Mohla S, White S, Grzegorzewski K, Nielsen D, Dunston G, Dickson L, Cha JK, Asseffa A, Olden K. Inhibition of growth of subcutaneous xenografts and metastasis of human breast-carcinoma by swainsonine - modulation of tumor-cell Hla class-I antigens and host immune effector mechanisms. Anticancer Res 1990;10:1515-1522.
20. Kumar NS, Pinto BM. Synthesis of thioswainsonine as a potential glycosidase inhibitor. Carbohydr Res 2006;341:1685-1691.
21. Kumar NS, Pinto BM. Synthesis of a sulfonium ion analogue of the glycosidase inhibitor swainsonine. J Org Chem 2006;71:1262-1264.
22. Svansson L, Johnston BD, Gu JH, Patrick B, Pinto BM. Synthesis and conformational analysis of a sulfonium-ion analogue of the glycosidase inhibitor castanospermine. J Am Chem Soc 2000;122:10769-10775.
23. Kumar NS, Pinto BM. Synthesis and conformational analysis of bicyclic sulfonium salts. Structures related to the glycosidase inhibitor australine. J Org Chem 2006;71:2935-2943.
24. Cere V, Pollicino S, Ricci A. New synthetic approach to enantiopure bicyclic sulfonium salts: swainsonine analogues. J Org Chem 2003;68:3311-3314.
25. Izquierdo I, Plaza MT, Aragon F. Enantiospecific synthesis of 8-O-methylthioswainsonine from a derivative of D-glucose. Tetrahedron: Asymmetry 1996;7:2567-2575.
26. Siriwardena A, Strachan H, El-Daher S, Way G, Winchester B, Glushka J, Moremen K, Boons GJ. Potent and selective inhibition of class II alpha-D-mannosidase activity by a bicyclic sulfonium salt. ChemBioChem 2005;6:845-848.
27. Rabouille C, Kuntz DA, Lockyer A, Watson R, Signorelli T, Rose DR, van den Heuvel M, Roberts DB. The Drosophila GMII gene encodes a Golgi alpha-mannosidase II. J Cell Sci 1999;112:3319-3330.
28. Shimizu T, Matsuhisa A, Kamigata N, Ikuta S. Activation-energies for pyramidal inversion of sulfonium, selenonium and telluronium ylides based on ab-initio mo calculations. J Chem Soc, Perkin Trans 2 1995:1805-1808.
29. Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 1980;36:3219-3228.
30. Gasteiger J, Marsili M. Prediction of proton magnetic-resonance shifts - the dependence on hydrogen charges obtained by iterative partial equalization of orbital electronegativity. Org Magn Reson 1981;15:353-360.
31. van den Elsen JMH, Kuntz DA, Rose DR. Structure of Golgi alpha-mannosidase II: a target for inhibition of growth and metastasis of cancer cells. EMBO J 2001;20:3008-3017.
32. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A 2nd generation force-field for the simulation of proteins, nucleic-acids, and organic-molecules. J Am Chem Soc 1995;117:5179-5197.
33. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-1662.
34. Bailey S. The CCP4 suite - programs for protein crystallography. Acta Crystallogr D Bio Crystallogr 1994;50:760-763.
35. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Bio Crystallogr 1998;54:905-921.
36. Lamzin VS, Perrakis A, Wilson KS. Crystallography of biological macromolecules. The ARP/WARP suite for automated construction and refinement of protein models. Int Tables Crystallogr 2001;F:720-722.
37. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Bio Crystallogr 2004;60:2126-2132.
38. Sheldrick GM, Schneider TR. SHELXL: high-resolution refinement. Methods Enzymol 1997;277:319-343.
39. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Bio Crystallogr 1997;53:240-255.
40. Numao S, Kuntz DA, Withers SG, Rose DR. Insights into the mechanism of Drosophila melanogaster Golgi alpha-mannosidase II through the structural analysis of covalent reaction intermediates. J Biol Chem 2003;278:48074-48083.
41. Lovering AL, Lee SS, Kim YW, Withers SG, Strynadka NCJ. Mechanistic and structural analysis of a family 31 alpha-glycosidase and its glycosyl-enzyme intermediate. J Biol Chem 2005;280:2105-2115.
42. Sulzenbacher G, Bignon C, Nishimura T, Tarling CA, Withers SG, Henrissat B, Bourne Y. Crystal structure of Thermotoga maritima alpha-L-fucosidase - insights into the catalytic mechanism and the molecular basis for fucosidosis. J Biol Chem 2004;279:13119-13128.
43. Kuntz DA, Ghavami A, Johnston BD, Pinto BM, Rose DR. Crystallographic analysis of the interactions of Drosophila melanogaster Golgi alpha-mannosidase II with the naturally occurring glycomimetic salacinol and its analogues. Tetrahedron: Asymmetry 2005;16:25-32.
44. Kawatkar SP, Kuntz DA, Woods RJ, Rose DR, Boons GJ. Structural basis of the inhibition of Golgi alpha-mannosidase II by mannostatin A and the role of the thiomethyl moiety in ligand-protein interactions. J Am Chem Soc 2006;128:8310-8319.
45. Li B, Kawatkar SP, George S, Strachan H, Woods RJ, Siriwardena A, Moremen KW, Boons GJ. Inhibition of Golgi mannosidase II with mannostatin a analogues: synthesis, biological evaluation, and structure-activity relationship studies. Chembiochem 2004;5:1220-1227.
46. Pearson WH, Hembre EJ. Synthesis and mannosidase inhibitory activity of 6-and 7-substituted analogs of swainsonine. Tetrahedron Lett 2001;42:8273-8276.
47. Clarke C, Woods RJ, Gluska J, Cooper A, Nutley MA, Boons GJ. Involvement of water in carbohydrate-protein binding. J Am Chem Soc 2001;123:12238-12247.
48. Gloster TM, Meloncelli P, Stick RV, Zechel D, Vasella A, Davies GJ. Glycosidase inhibition: an assessment of the binding of 18 putative transition-state mimics. J Am Chem Soc 2007;129:2345-2354.
49. Lemieux RU. How water provides the impetus for molecular recognition in aqueous solution. Acc Chem Res 1996;29:373-380.